Matches in SemOpenAlex for { <https://semopenalex.org/work/W2911850632> ?p ?o ?g. }
- W2911850632 endingPage "319" @default.
- W2911850632 startingPage "307" @default.
- W2911850632 abstract "Successful application of potent antibody-based T-cell engaging immunotherapeutic strategies is currently limited mainly to hematological cancers. One major reason is the lack of well-characterized antigens on solid tumors with sufficient cancer specific expression. Aberrantly O-glycosylated proteins contain promising cancer-specific O-glycopeptide epitopes suitable for immunotherapeutic applications, but currently only few examples of such antibody epitopes have been identified. We previously showed that chimeric antigen receptor T-cells directed towards aberrantly O-glycosylated MUC1 can control malignant growth in a mouse model. Here, we present a discovery platform for the generation of cancer-specific monoclonal antibodies targeting aberrant O-glycoproteins. The strategy is based on cancer cell lines engineered to homogeneously express the truncated Tn O-glycoform, the so-called SimpleCells. We used SimpleCells of different cancer origin to elicit monoclonal antibodies with selectivity for aberrant O-glycoproteins. For validation we selected and characterized one monoclonal antibody (6C5) directed to a Tn-glycopeptide in dysadherin (FXYD5), known to be upregulated in cancer and promote metastasis. While dysadherin is widely expressed also in normal cells, we demonstrated that the 6C5 epitope is specifically expressed in cancer." @default.
- W2911850632 created "2019-02-21" @default.
- W2911850632 creator A5000018452 @default.
- W2911850632 creator A5002466204 @default.
- W2911850632 creator A5006678037 @default.
- W2911850632 creator A5018411206 @default.
- W2911850632 creator A5030965826 @default.
- W2911850632 creator A5036375780 @default.
- W2911850632 creator A5039705405 @default.
- W2911850632 creator A5040558280 @default.
- W2911850632 creator A5049912825 @default.
- W2911850632 creator A5064352119 @default.
- W2911850632 creator A5073934804 @default.
- W2911850632 creator A5091343644 @default.
- W2911850632 date "2019-02-06" @default.
- W2911850632 modified "2023-10-16" @default.
- W2911850632 title "A strategy for generating cancer-specific monoclonal antibodies to aberrant<i>O</i>-glycoproteins: identification of a novel dysadherin-Tn antibody" @default.
- W2911850632 cites W136495174 @default.
- W2911850632 cites W1577788031 @default.
- W2911850632 cites W1654213728 @default.
- W2911850632 cites W1710371087 @default.
- W2911850632 cites W1902656581 @default.
- W2911850632 cites W1966649061 @default.
- W2911850632 cites W1976625658 @default.
- W2911850632 cites W1982232075 @default.
- W2911850632 cites W1989770075 @default.
- W2911850632 cites W1995611890 @default.
- W2911850632 cites W1997081950 @default.
- W2911850632 cites W1998419385 @default.
- W2911850632 cites W1998866479 @default.
- W2911850632 cites W2007058211 @default.
- W2911850632 cites W2007562801 @default.
- W2911850632 cites W2008263037 @default.
- W2911850632 cites W2009013652 @default.
- W2911850632 cites W2010859706 @default.
- W2911850632 cites W2011545537 @default.
- W2911850632 cites W2012018082 @default.
- W2911850632 cites W201357455 @default.
- W2911850632 cites W2014675555 @default.
- W2911850632 cites W2019101181 @default.
- W2911850632 cites W2022201255 @default.
- W2911850632 cites W2022314272 @default.
- W2911850632 cites W2022471636 @default.
- W2911850632 cites W2028417270 @default.
- W2911850632 cites W2032789303 @default.
- W2911850632 cites W2035023552 @default.
- W2911850632 cites W2037256359 @default.
- W2911850632 cites W2039093241 @default.
- W2911850632 cites W2039969458 @default.
- W2911850632 cites W2042579681 @default.
- W2911850632 cites W2044030139 @default.
- W2911850632 cites W2049436594 @default.
- W2911850632 cites W2050153157 @default.
- W2911850632 cites W2050859638 @default.
- W2911850632 cites W2058451329 @default.
- W2911850632 cites W2059282001 @default.
- W2911850632 cites W2061503461 @default.
- W2911850632 cites W2062186508 @default.
- W2911850632 cites W2070552573 @default.
- W2911850632 cites W2071653361 @default.
- W2911850632 cites W2072918899 @default.
- W2911850632 cites W2073865076 @default.
- W2911850632 cites W2074189907 @default.
- W2911850632 cites W2075253368 @default.
- W2911850632 cites W2076474832 @default.
- W2911850632 cites W2078799295 @default.
- W2911850632 cites W2081507143 @default.
- W2911850632 cites W2081660311 @default.
- W2911850632 cites W2086250032 @default.
- W2911850632 cites W2087304127 @default.
- W2911850632 cites W2087339901 @default.
- W2911850632 cites W2088149250 @default.
- W2911850632 cites W2089028882 @default.
- W2911850632 cites W2094945699 @default.
- W2911850632 cites W2099570622 @default.
- W2911850632 cites W2100925219 @default.
- W2911850632 cites W2101885441 @default.
- W2911850632 cites W2104557476 @default.
- W2911850632 cites W2104941784 @default.
- W2911850632 cites W2105400883 @default.
- W2911850632 cites W2107441560 @default.
- W2911850632 cites W2108168031 @default.
- W2911850632 cites W2111005494 @default.
- W2911850632 cites W2112241054 @default.
- W2911850632 cites W2112486118 @default.
- W2911850632 cites W2112689808 @default.
- W2911850632 cites W2118566883 @default.
- W2911850632 cites W2118796952 @default.
- W2911850632 cites W2119033790 @default.
- W2911850632 cites W2129254802 @default.
- W2911850632 cites W2129348400 @default.
- W2911850632 cites W2130338247 @default.
- W2911850632 cites W2131358717 @default.
- W2911850632 cites W2134860457 @default.
- W2911850632 cites W2137960319 @default.
- W2911850632 cites W2141175946 @default.
- W2911850632 cites W2148640160 @default.
- W2911850632 cites W2148688997 @default.